TSOI Therapeutic Solutions International Inc.

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbeneâ„¢ to Stimulate Immune System in Advanced Cancer Patients

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients

Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal

OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal. 

In the manuscript, 12 advanced cancer patients were treated for 3 weeks with 300mg daily administration of NanoStilbene™.  Immune parameters where assessed before treatment and at completion.  A substantial increase in activity of T cells and NK cells was observed as a result of treatment. 

It is known that NK cells are the first line of defense against cancer, and that T cells are the cellular basis for immunological memory which stops cancer from coming back.  Mechanistically, the authors believed that an increase in immune response was the result of immune suppression in cancer-associated inflammation by NanoStilbene™ [1].  It is known that the active ingredient in NanoStilbene™, called pterostilbene, is a potent inhibitor of inflammation.

"There are numerous cancer therapies whose efficacy is controlled by the activity of the immune system.  Treatments such as radiation therapy, have now been shown to be actively amplified by a strong immune system," said Dr. James Veltmeyer MD, Chief Medical Officer of the Company, and co-author of the paper. "Furthermore, it has been demonstrated that the activity of drugs such as the multi-billion dollar a year monoclonal antibody Herceptin, are dependent on an intact NK compartment."

The Company is currently selling NanoStilbene™ as a nutraceutical and is working with several naturopathic, allopathic, integrative, and alternative medicine doctors at identifying optimum doses and combination with other drugs.

"There is a trend in oncology towards providing patients with drugs that not only kill tumors, but also have a reduced toxicity profile.  Based on my experiences, I believe NanoStilbene™ is a very promising safe, non-toxic nutraceutical adjuvant, and I am proud to be involved in its scientific development and evaluation," said Thomas Ichim, Ph.D., Board Member of TSOI and co-author of paper.

"We are honored to have such an accomplished team of collaborators that included Dr. Santosh Kesari, Senior Author of the submitted paper, and Dr. Feng Lin a distinguished tumor immunologist. To have scientists of this caliber work with us at designing, executing, and now hopefully publishing the reviewed results of this important clinical trial, is the culmination of four years of work that began with the filing of our issued US Patent 9,682,047 and the submission of this manuscript on the 23rd of August," said Timothy Dixon, President and CEO of the Company. "Our aim is to have a world without cancer, and we believe one very important advancement towards this is the integration of immunotherapies with other interventions such as our nanoformulation of pterostilbene."



About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is and e-commerce at .



[1]

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc.

EN
26/08/2019

Underlying

Reports on Therapeutic Solutions International Inc.

 PRESS RELEASE

Therapeutic Solutions International Successfully Treats “No Option” Pa...

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today successful treatment of 15 recent patients under the Right to Try Law with the Company’s universal donor JadiCell™ adult stem cell product. All patients displayed no adverse events and demonstrated subjective and objective levels of improvement. There were 12 COVID-19 patients who underwent a profound recovery despite advanced stage of disease, while the retired Navy SEAL that was previously publicly disclosed1 along with two other retired SEALS, had a significant decrease in biomarkers associated ...

 PRESS RELEASE

Therapeutic Solutions International Reports NanoStilbeneâ„¢ Protects t...

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market OCEANSIDE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Therapeutics Solutions International, Inc., () announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.  Neutropenia is an...

 PRESS RELEASE

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chie...

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA OCEANSIDE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today the recruitment of Feng Lin, MD, Ph.D., as Chief Scientific Officer.  Dr. Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery an...

 PRESS RELEASE

Therapeutic Solutions International Inc. Reports Revenues Up 850% for ...

Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2 OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as compared to the same period in 2018.  These increases were due primarily to the commercialization of NanoStilbene™ following the completion of clinical program that included a pharmacokinetic trial and a pilot cancer study in advanced cancer patients using 300mg of nanoparticle pterostilbene. As , results of this clinical...

 PRESS RELEASE

Therapeutic Solutions International Announces Positive Clinical Data U...

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.  In the manuscript, 12 advanced cancer patients were treated...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch